Research programme: peptidomimetic therapeutics - Ra Pharmaceuticals

Drug Profile

Research programme: peptidomimetic therapeutics - Ra Pharmaceuticals

Alternative Names: Cyclomimetics™; RA 101348

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ra Pharmaceuticals
  • Class Peptidomimetics; Small molecules
  • Mechanism of Action Complement C5 inhibitors; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Paroxysmal nocturnal haemoglobinuria
  • No development reported Hereditary angioedema

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Hereditary-angioedema in USA (PO)
  • 04 Dec 2014 Preclinical trials in Paroxysmal nocturnal haemoglobinuria in USA (SC)
  • 16 May 2012 Early research in Hereditary angioedema in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top